Hang-Qi Hu, Xiyan Xin, Yuming Zhu, Rui Fan, Hao-Lin Zhang, Yang Ye, Dong Li
{"title":"Application of mesenchymal stem cell therapy for premature ovarian insufficiency: Recent advances from mechanisms to therapeutics","authors":"Hang-Qi Hu, Xiyan Xin, Yuming Zhu, Rui Fan, Hao-Lin Zhang, Yang Ye, Dong Li","doi":"10.4252/wjsc.v16.i1.1","DOIUrl":null,"url":null,"abstract":"The incidence of premature ovarian insufficiency (POI) is increasing worldwide, particularly among younger women, posing a significant challenge to fertility. In addition to menopausal symptoms, POI leads to several complications that profoundly affect female reproductive function and overall health. Unfortunately, current clinical treatment strategies for this condition are limited and often yield unsatisfactory outcomes. These approaches typically involve hormone replacement therapy combined with psychological support. Recently, mesenchymal stem cell (MSC) therapies for POI have garnered considerable attention in global research. MSCs can restore ovarian reproductive and endocrine functions through diverse mechanisms, including controlling differentiation, promoting angiogenesis, regulating ovarian fibrosis, inhibiting apoptosis, enhancing autocrine and paracrine effects, suppressing inflammation, modulating the immune system, and genetic regulation. This editorial offers a succinct summary of the application of MSC therapy in the context of POI, providing evidence for groundbreaking medical approaches that have potential to enhance reproductive health and overall well-being for women.","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of stem cells","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4252/wjsc.v16.i1.1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
Abstract
The incidence of premature ovarian insufficiency (POI) is increasing worldwide, particularly among younger women, posing a significant challenge to fertility. In addition to menopausal symptoms, POI leads to several complications that profoundly affect female reproductive function and overall health. Unfortunately, current clinical treatment strategies for this condition are limited and often yield unsatisfactory outcomes. These approaches typically involve hormone replacement therapy combined with psychological support. Recently, mesenchymal stem cell (MSC) therapies for POI have garnered considerable attention in global research. MSCs can restore ovarian reproductive and endocrine functions through diverse mechanisms, including controlling differentiation, promoting angiogenesis, regulating ovarian fibrosis, inhibiting apoptosis, enhancing autocrine and paracrine effects, suppressing inflammation, modulating the immune system, and genetic regulation. This editorial offers a succinct summary of the application of MSC therapy in the context of POI, providing evidence for groundbreaking medical approaches that have potential to enhance reproductive health and overall well-being for women.
卵巢早衰(POI)的发病率在全球范围内不断上升,尤其是在年轻女性中,给生育带来了巨大挑战。除了更年期症状外,POI 还会导致多种并发症,严重影响女性的生殖功能和整体健康。遗憾的是,目前针对这种病症的临床治疗策略非常有限,而且效果往往不尽如人意。这些方法通常包括激素替代疗法和心理支持。最近,间充质干细胞(MSC)治疗 POI 在全球研究中引起了广泛关注。间充质干细胞可通过多种机制恢复卵巢生殖和内分泌功能,包括控制分化、促进血管生成、调节卵巢纤维化、抑制细胞凋亡、增强自分泌和旁分泌效应、抑制炎症、调节免疫系统和遗传调节。这篇社论简明扼要地总结了间充质干细胞疗法在 POI 方面的应用,为开创性的医疗方法提供了证据,这些方法有可能提高妇女的生殖健康和整体福祉。
期刊介绍:
The World Journal of Stem Cells (WJSC) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of stem cells. It was launched on December 31, 2009 and is published monthly (12 issues annually) by BPG, the world''s leading professional clinical medical journal publishing company.